the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
27.5 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

Memorandum on medical use of ketum, cannabis to be handed over to PM next week: Zahidi

KUALA LUMPUR: A memorandum based on the findings of a public forum entitled ‘Sustainable Future of Medical Cannabis, Industrial Hemp and Kratom (Ketum) Industry’ is expected to be handed over to Prime Minister Datuk Seri Ismail Sabri Yaakob by next week.

Deputy Communications and Multimedia Minister Datuk Zahidi Zainul Abidin (pix) said the move was to enable the crops to be used in the medical industry and exported.

He said immediate steps to approve the crop to be exported and used as a medicinal material were necessary to prevent Malaysia from being left behind in patenting the material.

“International drug agencies from the United States and Germany are in the process of patenting ketum (as a medicinal material), if we are slow in getting the approval, the country will lose out.

“If we are slow to patent it, then our country which grows ketum will have to pay high fees to export it abroad, even if they (other countries) do not grow it,“ he said during a press conference here today.

He said the memorandum would also be submitted to the Home and Health ministries.

At the same time, Zahidi said he would submit a memorandum of findings to all menteris besar and chief ministers on the effectiveness of the crops’ use in medicine, as well as get the support of MPs to amend the Poisons Act 1952.

“We will meet every Menteri Besar (and Chief Minister) and submit medical journals from universities, such as the University of Thailand which reports on the benefits of ketum for the nerves, and Universiti Sains Malaysia (USM) which has also done studies.

A research report on the benefits of cannabis, hemp and ketum and the memorandum were submitted to Zahidi at the public forum on Dec 16 last year. — Bernama

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings